ClinicalTrials.gg
CompletedNCT01100684Updated Dec 18, 2013

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

A Phase 3 interventional study of Asimadoline and Placebo in Diarrhea Predominant Irritable Bowel Syndrome, sponsored by Tioga Pharmaceuticals. Completed at 142 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by Tioga Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
611
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 249 studies in Diarrhea with a site in United States — 15 open to participants now, 20 under way, none of them phase 3. Diarrhea · United States.

Enrollment
20th of 223
611 · median 63
Started
2010
with 17 others
Phase 3
34 of 249
none open now
Registered
88th of 249
by date

Among the 249 studies in Diarrhea with a site in United States, this one is the 20th largest by enrollment of the 223 interventional ones that give a count, is one of 18 that started in 2010, is one of 34 in phase 3, and was the 88th registered.

Diarrhea

879 studies on the registry are indexed under Diarrhea; 77 are open to participants now.

Browse Diarrhea studies →

Open to participants now

15 of the 249 studies in Diarrhea with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Diarrhea with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether asimadoline is safe and effective at treating D-IBS.

Read the detailed description

The primary objective of the study is to compare the efficacy of the two treatments with respect to improvement in IBS-related abdominal pain severity and reduction in stool frequency. During the 12-week treatment period, daily IBS-related abdominal pain severity score and daily frequency of bowel movements will be averaged over each week to determine average values for each endpoint. For each subject, weekly response to treatment will be based on the following parameters:

  • Decrease from baseline of at least 30% in the average IBS-related daily abdominal pain severity score
  • Decrease from baseline of at least 25% in the average number of daily bowel movements A subject must meet both criteria to be considered a weekly responder. The primary efficacy endpoint is based on an "overall study responder," defined as a subject having 6 or more weeks of weekly response to treatment out of the 12 weeks in the treatment period. Overall study responder will be stratified by timing of bowel preparation and endoscopy.
03

Conditions studied

  • Diarrhea Predominant Irritable Bowel Syndrome

Keywords

  • diarrhea predominant irritable bowel syndrome
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signs and dates a written form.
  2. Male and female subjects aged 18-79 who are fluent in English
  3. All subjects must use protocol specified measures
  4. The subject is or has been diagnosed with IBS with symptom onset at least 6 months prior to diagnosis. IBS is defined as the subject having recurrent abdominal pain or discomfort at least 3 days per month in the past 3 months associated with at least two of the following symptoms:

    Improvement with defecation Onset associated with a change in frequency of stool Onset associated with a change in form (appearance) of stool

  5. The subject has been diagnosed with diarrhea-predominant IBS
  6. Within 2 years of the randomization visit, the subject has normal results from a flexible sigmoidoscopy, a colonoscopy, or a barium enema plus flexible sigmoidoscopy, according to the subject's age by a specified algorithm.

Exclusion criteria

Exclusion Criteria:

  1. The subject exhibits evidence of a biochemical or structural abnormality of the digestive tract.
  2. Subject has a concurrent illness or disability (excluding IBS) that may affect the interpretation of clinical efficacy and/or safety data or otherwise contraindicates participation in this clinical study (e.g., an unstable cardiovascular, renal, hepatic, pulmonary, endocrine, metabolic, GI, hematological, or neurological condition).
  3. The subject has a family history of prolonged syndrome.
  4. The subject has been diagnosed with a major psychiatric disorder.
  5. The subject has a history of alcohol or substance abuse within the past 2 years.
  6. The subject has a history or current evidence of laxative abuse
  7. The subject has a positive stool sample for ova or parasite.
  8. The subject has used an drug or participated in an investigational study within 30 days of screening.
  9. The subject refuses to discontinue one (or more) prohibited medications at least 7 days prior to the screening visit.
  10. The subject refuses to maintain a stable dose of one (or more) allowable concurrent medications for at least 30 days prior to the screening visit.
  11. The subject is a pregnant woman or a woman who is breast feeding.
  12. The subject is unable or unwilling to follow directions or use the electronic diary system.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
611 participants (actual)

Study arms

  • Experimental
    Treatment

    0.5 mg asimadoline bid

    Drug: Asimadoline

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • 0.5 mg Asimadoline BID

    Also known as: EMD 61 753, EMR 63 320

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. 12 Week Abdominal Pain and Stool (APS) Frequency Responder

    A study responder is a subject who has both a decrease from baseline of IBS-related abdominal pain and a decrease from baseline of daily bowel movements

    Time frame: Weekly responder based on patient assessments made daily in each week of the 12-week Treatment Period to determine 12 week APS responder

Secondary outcomes

  1. Compare the two treatment groups with respect to IBS-related abdominal pain

    Time frame: Up to 12 weeks

  2. Compare the two treatment groups with respect to stool frequency

    Time frame: Up to 12 weeks

  3. Compare the two treatment groups with respect to stool urgency

    Time frame: Up to 12 weeks

  4. Compare the two treatment groups with respect to IBS symptoms

    Time frame: up to 12 weeks

  5. Compare the two treatment groups with respect to stool consistency scores

    Using the Bristol Stool Form Scale

    Time frame: Up to 12 weeks

  6. Incidence of adverse events as a measure of tolerability

    Time frame: Up to 16 weeks

  7. Abnormalities of laboratory tests as a measure of tolerability

    Time frame: Up to 16 weeks

07

Study locations

142 sites
  • North Alabama Research Center, LLC
    Athens, Alabama 35611, United States
  • Alliance Clinical Research
    Birmingham, Alabama 35213, United States
  • Medical Affliated Research Center, Inc.
    Huntsville, Alabama 35801, United States
  • Saadat Ansari MD LLC
    Huntsville, Alabama 35801, United States
  • Connect Clinical Research Center
    Chandler, Arizona 85224, United States
  • Digestive Health Research Unit
    Scottsdale, Arizona 85260, United States
  • Adobe Clinical Research, LLC
    Tucson, Arizona 85712, United States
  • ACRC/Arizona Clinical Research Center, Inc.
    Tucson, Arizona 85715, United States
  • Genova Clinical Research
    Tucson, Arizona 85741, United States
  • W/C Clinical Research
    Tucson, Arizona 85741, United States
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72205, United States
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72212, United States
  • Arkansas Gastroenterology
    Sherwood, Arkansas 72120, United States
  • Providence Clinical Research
    Burbank, California 91505, United States
  • GW Research Inc,
    Chula Vista, California 91910, United States
  • La Jolla Clinical Research, Inc
    Chula Vista, California 91911, United States
  • Discovery Clinical Research
    Encinitas, California 92024, United States
  • Digestive & Liver Disease Specialist
    Garden Grove, California 92840, United States
  • Collaborative Neuroscience Network Inc
    Long Beach, California 90808, United States
  • California Gastroenterology Associates
    Madera, California 93637, United States
  • Community Clinical Trials
    Orange, California 92868, United States
  • Sutter Medical Group Gastroenterology
    Sacramento, California 95816, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • Medical Associates Research Group, Inc.
    San Diego, California 92123, United States
  • Westlake Medical Research
    Westlake Village, California 91361, United States
  • Lynne Institute of the Rockies
    Colorado Springs, Colorado 80907, United States
  • Arapahoe Gastroenterology
    Littleton, Colorado 80120, United States
  • Lynn Institute of Pueblo
    Pueblo, Colorado 81008, United States
  • Rocky Mountain Gastroenterology Associates
    Thornton, Colorado 80229, United States
  • Danbury Clinical Research, LLC
    Danbury, Connecticut 06810, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Consultants for Clinical Research of South Florida
    Boynton Beach, Florida 33426, United States
  • Meridien Research
    Brookville, Florida 34601, United States
  • BioPharma Research
    Coral Gables, Florida 33134, United States
  • Riverside Clinical Research
    Edgewater, Florida 32132, United States
  • A.G.A. Clinical Trials
    Hialeah, Florida 33012, United States
  • Altus Research
    Lake Worth, Florida 33461, United States
  • Center for Advanced Gastroenterology
    Maitland, Florida 32751, United States
  • FIRC
    Miami, Florida 33166, United States
  • DMI Research
    Pinellas Park, Florida 33782, United States
  • Accord Clinical Research, LLC
    Port Orange, Florida 32129, United States
  • International Clinical Research-US,LLC
    Sanford, Florida 32771, United States
  • Lakeview Medical Research
    Summerfield, Florida 34491, United States
  • Venra Clinical Studies, LLC
    Wellington, Florida 33414, United States
  • Alliance Clinical Research
    Winter Park, Florida 32792, United States
  • Atlanta Center for Gastroenterology
    Decatur, Georgia 30033, United States
  • Tri County Research
    Hartwell, Georgia 30643, United States
  • Northwest Gastroenterologist S.C.
    Arlington Heights, Illinois 60005, United States
  • Illinois Center for Clinical Research
    Chicago, Illinois 60622, United States
  • Southwest Gastroenterology
    Oak Lawn, Illinois 60453, United States
  • Elkhart Clinic, LLC/Indiana Medical Research, LLC
    Elkhart, Indiana 46514, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • Mercy Gastroenterology Clinic
    Clive, Iowa 50325, United States
  • Gastrointestinal Clinic of Quad Cities
    Davenport, Iowa 52807, United States
  • Heartland Research Associates, LLC
    Newton, Kansas 67114, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Graves-Gilbert Clinic
    Bowling Green, Kentucky 42101, United States
  • Tri-State Gastroenterology Associates, PSC
    Crestview Hills, Kentucky 41017, United States
  • Hometown Urgent Care and Research
    Hebron, Kentucky 41048, United States
  • The Research Group of Lexington, LLC
    Lexington, Kentucky 40504, United States
  • University of Louisville Medical-Dental Complex
    Louisville, Kentucky 40202, United States
  • Tover Health Systems Center for Clinical Research
    Madisonville, Kentucky 42431, United States
  • Investigative Clinical Research
    Annapolis, Maryland 21401, United States
  • Meritus Center for Clinical Resarch
    Hagerstown, Maryland 21742, United States
  • Spectrum Clinical Research Inc.
    Towson, Maryland 21204, United States
  • Commonwealth Clinical Studies
    Brockton, Massachusetts 02302, United States
  • NECCR Internal Medicine and Cardiology Associates LLC
    Fall River, Massachusetts 02720, United States
  • ActivMed Practices and Research
    Haverhill, Massachusetts 01830, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48009, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Saginaw Valley Medical Research Group, LLC
    Saginaw, Michigan 48604, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Gastrointestinal Accociates, PA
    Jackson, Mississippi 39202, United States
  • Digestive Research Specialist
    Tupelo, Mississippi 38801, United States
  • Midwest Center for Clinical Research
    Lees Summit, Missouri 64064, United States
  • Center for Digestive and Liver Diseases, Inc.
    Mexico, Missouri 65265, United States
  • St. Louis Center for Clinical Research
    St. Louis, Missouri 63128, United States
  • Montana Health Research Institute, Inc.
    Billings, Montana 59102, United States
  • Dr. Meera Dewan PC
    Omaha, Nebraska 68144, United States
  • Anderson & Collins Clinical Research
    Edison, New Jersey 08817, United States
  • South Jersey Gastroenterology. P.A.
    Marlton, New Jersey 08053, United States
  • Atlantic Research Affiliates
    Morristown, New Jersey 07960, United States
  • Life Medi-Research
    Brooklyn, New York 11206, United States
  • Long Island Clinical Research Associates, LLP
    Great Neck, New York 11021, United States
  • Long Island Gastrointestinal Research Group
    Great Neck, New York 11023, United States
  • Winthrop University Hospital Clinical Trials Center
    Mineola, New York 11501, United States
  • Research Associates of New York
    New York,, New York 10075, United States
  • Premier Medical Group of the Hudson Valley
    Poughkeepsie, New York 12601, United States
  • Gastrointestinal Research Associates, LLC
    Setauket, New York 11733, United States
  • The UNC Center for Functional GI and Motility Disorders
    Chapel Hill, North Carolina 27599, United States
  • PMG Research of Charlotte, LLC
    Charlotte, North Carolina 28209, United States
  • LeBauer Research Associates, P.A.
    Greensboro, North Carolina 27403, United States
  • PMG Research of Hickory, LLC
    Hickory, North Carolina 28602, United States
  • Peters Medical Research
    High Point, North Carolina 27262, United States
  • Kinston Medical Specialist, P.A.
    Kinston, North Carolina 28501, United States
  • Wake Research Associates
    Raleigh, North Carolina 27616, United States
  • Trial Management Associates LLC
    Wilmington, North Carolina 28403, United States
  • PMG Research of Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58103, United States
  • Akron Gastroenterology Associates
    Akron, Ohio 44302, United States

Showing the first 100 of 142 sites. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2010
First posted
Apr 9, 2010
Start
May 2010
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Dec 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01100684
Lead sponsor
Tioga Pharmaceuticals
Collaborators
RTI Health Solutions
Responsible party
Sponsor
First posted
Apr 9, 2010
Start date
May 2010
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Dec 18, 2013

Study contacts

Allen Mangel, M.D.Ph.D.
study chair · CMO

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asimadoline

Start the discussion